Logo image of ADVM

ADVERUM BIOTECHNOLOGIES INC (ADVM) Stock Fundamental Analysis

USA - NASDAQ:ADVM - US00773U2078 - Common Stock

2.95 USD
+0.07 (+2.43%)
Last: 9/18/2025, 8:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ADVM. ADVM was compared to 540 industry peers in the Biotechnology industry. While ADVM seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ADVM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADVM has reported negative net income.
ADVM had a negative operating cash flow in the past year.
ADVM had negative earnings in each of the past 5 years.
In the past 5 years ADVM always reported negative operating cash flow.
ADVM Yearly Net Income VS EBIT VS OCF VS FCFADVM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -71.49%, ADVM is not doing good in the industry: 62.78% of the companies in the same industry are doing better.
ADVM has a Return On Equity of -181.81%. This is in the lower half of the industry: ADVM underperforms 65.19% of its industry peers.
Industry RankSector Rank
ROA -71.49%
ROE -181.81%
ROIC N/A
ROA(3y)-63.55%
ROA(5y)-49.62%
ROE(3y)-136.88%
ROE(5y)-96.75%
ROIC(3y)N/A
ROIC(5y)N/A
ADVM Yearly ROA, ROE, ROICADVM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ADVM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADVM Yearly Profit, Operating, Gross MarginsADVM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

ADVM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADVM has more shares outstanding
Compared to 5 years ago, ADVM has more shares outstanding
There is no outstanding debt for ADVM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ADVM Yearly Shares OutstandingADVM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ADVM Yearly Total Debt VS Total AssetsADVM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -9.75, we must say that ADVM is in the distress zone and has some risk of bankruptcy.
ADVM has a worse Altman-Z score (-9.75) than 71.85% of its industry peers.
There is no outstanding debt for ADVM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.75
ROIC/WACCN/A
WACC9.57%
ADVM Yearly LT Debt VS Equity VS FCFADVM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ADVM has a Current Ratio of 5.73. This indicates that ADVM is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ADVM (5.73) is better than 61.30% of its industry peers.
A Quick Ratio of 5.73 indicates that ADVM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.73, ADVM is in the better half of the industry, outperforming 61.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.73
Quick Ratio 5.73
ADVM Yearly Current Assets VS Current LiabilitesADVM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.75% over the past year.
The Revenue for ADVM has decreased by -72.22% in the past year. This is quite bad
ADVM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.95% yearly.
EPS 1Y (TTM)1.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-162.92%
Revenue 1Y (TTM)-72.22%
Revenue growth 3Y-48.91%
Revenue growth 5Y31.95%
Sales Q2Q%N/A

3.2 Future

ADVM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.19% yearly.
ADVM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 134.50% yearly.
EPS Next Y5.04%
EPS Next 2Y27.92%
EPS Next 3Y17.7%
EPS Next 5Y11.19%
Revenue Next Year1798.73%
Revenue Next 2Y-32.81%
Revenue Next 3Y-24.61%
Revenue Next 5Y134.5%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADVM Yearly Revenue VS EstimatesADVM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ADVM Yearly EPS VS EstimatesADVM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADVM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADVM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADVM Price Earnings VS Forward Price EarningsADVM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADVM Per share dataADVM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as ADVM's earnings are expected to grow with 17.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.92%
EPS Next 3Y17.7%

More info and screens

0

5. Dividend

5.1 Amount

ADVM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVERUM BIOTECHNOLOGIES INC

NASDAQ:ADVM (9/18/2025, 8:00:00 PM)

2.95

+0.07 (+2.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-05 2025-11-05/amc
Inst Owners72.57%
Inst Owner Change-13.31%
Ins Owners12.17%
Ins Owner Change0.98%
Market Cap61.89M
Analysts80
Price Target19.89 (574.24%)
Short Float %5.83%
Short Ratio9.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.46%
Min EPS beat(2)-41.41%
Max EPS beat(2)2.5%
EPS beat(4)2
Avg EPS beat(4)-0.76%
Min EPS beat(4)-41.41%
Max EPS beat(4)40.56%
EPS beat(8)5
Avg EPS beat(8)5.77%
EPS beat(12)6
Avg EPS beat(12)-0.32%
EPS beat(16)8
Avg EPS beat(16)0.39%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.27%
PT rev (3m)-15.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)14.28%
EPS NY rev (3m)2.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)9893.29%
Revenue NY rev (3m)11892.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 61.89
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-7.85
EYN/A
EPS(NY)-2.05
Fwd EYN/A
FCF(TTM)-4.43
FCFYN/A
OCF(TTM)-4.41
OCFYN/A
SpS0.05
BVpS3.37
TBVpS3.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.49%
ROE -181.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.55%
ROA(5y)-49.62%
ROE(3y)-136.88%
ROE(5y)-96.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.62%
Cap/Sales 38.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.73
Quick Ratio 5.73
Altman-Z -9.75
F-Score3
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)68.65%
Cap/Depr(5y)163.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-162.92%
EPS Next Y5.04%
EPS Next 2Y27.92%
EPS Next 3Y17.7%
EPS Next 5Y11.19%
Revenue 1Y (TTM)-72.22%
Revenue growth 3Y-48.91%
Revenue growth 5Y31.95%
Sales Q2Q%N/A
Revenue Next Year1798.73%
Revenue Next 2Y-32.81%
Revenue Next 3Y-24.61%
Revenue Next 5Y134.5%
EBIT growth 1Y-10.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-79.65%
EBIT Next 3Y-33.28%
EBIT Next 5Y-28.82%
FCF growth 1Y-1.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.72%
OCF growth 3YN/A
OCF growth 5YN/A